Infectious diseases of the eye can be caused by bacteria, viruses, fungi, protozoa, and metazoa.
Topical antimicrobial application is the mainstay of treatment of bacterial infections causing corneal and conjunctival disease, although subconjunctival injections can provide a depot effect, mainly in large animals. The systemic route is used mainly for eyelid, intraocular, and orbital disease. Some diseases may initially present with ocular signs, although they are associated with systemic changes (eg, Chlamydia felis) causing conjunctivitis and respiratory disease. In these cases a combination of routes can be used.
Antimicrobials are classified a number of different ways, ie, by drug class, effect on bacteria (bacteriostatic or bactericidal), bacterial spectrum (gram-positive, gram-negative, or both), and efficacy against aerobic and anaerobic organisms. Topical antimicrobials can be used either to prevent or treat disease. The clinical presentation will determine the choice of drug. These drugs can be used alone or in combination with each other. Certain antimicrobials, such as neomycin, gramicidin, bacitracin, polymyxin B, and fusidic acid, are too toxic to be used systemically; however, they can be used topically on the eye. Advantages of topical antimicrobials include a lower incidence of antimicrobial resistance, ability to administer higher concentrations, and less systemic adverse effects. Clinically, it is easier to consider topical ophthalmic antimicrobial drops by their spectrum of activity rather than by class. For a discussion of their detailed pharmacology, see Pharmacology Overview of Pharmacology After a diagnosis is made and medical treatment is deemed necessary, safe and effective pharmacological agents that exert the appropriate actions should be selected. A dosing regimen should... read more and Antibacterial Agents Antibacterial Agents .
Antimicrobials for Broad Spectrum Infections of the Eye in Animals
Families of topical ophthalmic drugs with both a gram-positive and gram-negative spectrum include aminoglycosides, fluoroquinolones, chloramphenicol, tetracyclines, and the macrolides.
Ophthalmic aminoglycoside formulations include neomycin, framycetin (neomycin B), gentamicin, and tobramycin. Injectable amikacin can be compounded into a topical formulation. As a family the aminoglycosides are all bactericidal, mainly against aerobic gram-negative bacteria. They vary in their efficacy against Pseudomonas spp. Neomycin has no activity against Pseudomonas; gentamicin has some, although there is more resistance; tobramycin and amikacin treat resistant Pseudomonas. Aminoglycosides have some gram-positive activity against staphylococci but not streptococci. They bind irreversibly to the 30S subunit and, by causing misreading of the mRNA, result in incorrect amino acid incorporation, thus inhibiting ribosomal protein synthesis. They are hydrophilic and have poor penetration across an intact cornea. High concentrations of gentamicin are epitheliotoxic, and very frequent dosing can slow corneal epithelialization during ulcer healing.
In humans, topical ophthalmic neomycin can be highly toxic and allergenic. There are reports of similar problems in animals, especially cats. Neomycin is still used commonly in combination drops; however, care needs to be taken that the presence of conjunctivitis during and after treatment is due to disease rather than a local toxic or allergic drug reaction. Gentamicin can be injected into the vitreous in dogs and horses for ciliary body ablation in animals with blind, painful eyes from chronic glaucoma Glaucoma in Animals Acute glaucoma in a Cocker Spaniel's eye: episcleral injection and diffuse corneal edema are visible. The pupil is dilated. This dog had an intraocular pressure of 55 mm Hg (normal is < 20mmHg)... read more . Care needs to be taken in small dogs that the toxic dose is not reached. Low dose (4 mg) intravitreal gentamicin is also used to help treat equine recurrent uveitis Equine Recurrent Uveitis . Complications can include cataract formation or maturation and retinal degeneration.
Fluoroquinolones are synthetic compounds based on a 4-quinolone nucleus. Chemical modification of this nucleus by substitution with a fluorine and addition/substitution of other chemical groups has improved the drug’s spectrum. The first fluoroquinolones were efficacious against gram-negative bacteria; subsequent generations are effective against gram-positive, atypical bacterial, Mycoplasma spp, and anaerobic bacteria. As a family, fluoroquinolones are bactericidal and have a post-antimicrobial effect against some bacteria. Their efficacy does not appear to be inhibited by the presence of mucopurulent material; thus, they are effective for treating corneal or conjunctival disease or the presence of hypopyon. Fluoroquinolones act by targeting bacterial topoisomerases II (DNA gyrase) and IV. Topoisomerase II is involved in interrupting the DNA-breakage and reunion step involved in negative supercoiling of DNA within the cell. Topoisomerase IV helps with the ATP-dependent relaxation of DNA.
Members of this family have been grouped into generations based on their antibacterial spectrum. This spectrum variation against gram-positive and gram-negative bacteria is thought to be associated with the level of activity against one or both topoisomerases. Second-generation compounds such as ciprofloxacin and ofloxacin have an increased gram-negative spectrum, including Pseudomonas aeruginosa, a common cause of melting corneal ulcers. Third- and fourth-generation compounds (levofloxacin, moxifloxacin, gatofloxacin, besifloxacin) have increased activity against gram-positive bacteria such as beta-hemolytic streptococci and atypical organisms such as Chlamydophila and Mycoplasma. However, they have decreased efficacy against P aeruginosa. As a group, the fluoroquinolones are used topically for infectious conjunctivitis and corneal ulcers. All topical products are used off-label. Too-frequent use (more than every 6 hours) in the treatment of corneal ulcers can cause corneal epithelial cell toxicity and enhancement of corneal melting due to induced expression of matrix metalloproteinases.
Oral formulations include enrofloxacin, marbofloxacin, orbifloxacin (second generation), and pradofloxacin (third generation), which can be used in treatment of Rickettsia spp, Chlamydia, and Mycoplasma spp. The fluoroquinolones are lipophilic and have good intraocular penetration when used topically and systemically. Irreversible retinal toxicity has been seen in cats after administration of enrofloxacin at dosages of 20 mg/kg or higher. The manufacturer has recommended a dosage of 5 mg/kg/day. Orbifloxacin administered orally to cats at 45 mg/kg did show some retinal hyper-reflectivity in the area centralis and some photoreceptor degeneration.
The amphenicol antimicrobials include chloramphenicol, thiamphenicol, and florfenicol. Chloramphenicol inhibits protein synthesis at the 50S ribosomal subunit. The mechanism of action of thiamphenicol and florfenicol is similar to chloramphenicol. Chloramphenicol is regarded as being bacteriostatic against gram-positive (S pseudointermedius, S aureus, streptococci), some gram-negative bacteria, anaerobic bacteria, and intracellular organisms such as Mycoplasma spp and Chlamydia. Chloramphenicol is lipophilic and easily crosses the cornea into the anterior chamber. Florfenicol has a similar spectrum and may be bactericidal against S pseudointermedius. It is also effective in treating infectious bovine keratoconjunctivitis Infectious Keratoconjunctivitis in Animals Infectious keratoconjunctivitis of cattle, sheep, and goats is a common ocular condition characterized by blepharospasm, conjunctivitis, lacrimation, and varying degrees of corneal opacity and... read more when used subcutaneously or intramuscularly. In many countries, chloramphenicol cannot be legally used in food animals. The concern is the risk of irreversible aplastic anemia in humans associated with the par-nitro group of the molecule.
The tetracycline family of drugs includes tetracycline, oxytetracycline, chlortetracycline, doxycycline, and minocycline. They act by reversibly binding to the 30S ribosome and interfere with the binding of transfer RNA to messenger RNA, subsequently inhibiting protein synthesis. They are regarded as being bacteriostatic and a constant drug concentration is required for efficacy. They are amphoteric and highly lipophilic and have good intraocular penetration when applied topically and administered orally or parenterally. They are effective against gram-positive and gram-negative bacteria as well as Chlamydia, Mycoplasma, hemoplasma, Ehrlichia, and Rickettsia. Doxycycline is used orally at 10 mg/kg once or 5 mg/kg every 12 hours for inhibition of matrix metalloproteinases in deep or melting corneal ulcers.
Macrolides and Azalides
Erythromycin is a macrocyclic lactone. The mechanism of action for this family is binding to the 50S ribosomal subunit and inhibiting protein synthesis via disruption of the translocation of mRNA. It is regarded as being bacteriostatic but can be bactericidal at higher concentrations. The antibacterial spectrum is predominately gram positive, against staphylococci and streptococci, including beta-lactam resistance staphylococci. The few gram-negative bacteria it is effective against are not common causes of ocular disease. Chlamydia and Mycoplasma are regarded as being resistant to erythromycin, and it is not regarded as the drug of choice in treating conjunctivitis. There is no efficacy against Pseudomonas spp, and it should not be used in the treatment of complicated corneal ulcers. Azithromycin is an azalide, a subclass of macrolides and is derived from erythromycin. It has a wider spectrum than erythromycin against gram-positive, gram-negative, and atypical organisms. The drug accumulates in higher concentrations in phagocytes and has been shown to have immunomodulatory effects. Oral azithromycin is not as effective as doxycycline in the treatment of feline respiratory disease due to C felis.
Antimicrobials for Gram-positive Only Infections of the Eye in Animals
Bacitracin is a polypeptide antimicrobial that in ophthalmology is only used in combination with other antimicrobials, usually an aminoglycoside and polymyxin B. It is bactericidal against most gram-positive bacteria and acts by inhibiting cell wall peptidoglycan synthesis at a different step than the beta-lactam antimicrobials. Resistance is rare.
Fusidic acid is a lipophilic steroid antimicrobial. The mechanism of action is to interfere with the function of elongation factor and inhibit protein synthesis at the 50S subunit of the ribosome. It is mainly bacteriostatic against gram-positive organisms (but is not a treatment of choice for corneal streptococci infections) and slowly bactericidal against Staphylococcus aureus. It is of limited use on its own for infections because resistance can develop quickly. In vitro, there is synergism with aminoglycosides and macrolides and can be antagonistic with fluoroquinolones.
Gramicidin is an ionophore peptide antimicrobial that creates ion channels in many gram-positive bacterial cell membranes and organelles. These channels disrupt ion concentration gradients leading to cell death. High concentrations are also toxic to mammalian cells. It is often combined with other drugs with different mechanisms of action (eg, polymyxin B, neomycin) to extend the spectrum of activity.
Fortified cefazolin (33 mg/mL), a first-generation cephalosporin, can be used in combination with an aminoglycoside or fluoroquinolone to treat stromal or melting ulcers. Cefazolin is bactericidal and like other beta-lactams, has post-antimicrobial effects. It acts by binding to penicillin-binding proteins and inhibiting the transpeptidation reaction involved in cell wall cross-linking. The spectrum is predominantly gram-positive (staphylococci and streptococci). Although there is some activity against gram-negative bacteria, most are not susceptible due to poor access to the cell wall and resistance due to beta-lactamases. Pseudomonas aeruginosa are resistant. High concentrations and too frequent topical application can be toxic to corneal epithelial cells and slow down healing.
Antimicrobials for Gram-negative Only Infections of the Eye in Animals
Polymyxin B is a detergent (surface-active agent) that disrupts the bacterial plasma membrane by binding to phospholipids. It is bactericidal against gram-negative bacteria and has a synergistic effect with ethylenediaminetetraacetic acid (EDTA) against P aeruginosa. Resistance is rare but can occur in P aeruginosa. It is used in combination with other antimicrobials with a gram-positive spectrum, eg, bacitracin, gramicidin.
Triple Antimicrobial Combinations
Topical antimicrobials are used to treat corneal ulcers. Unless the ulcer is deep or melting, culture and sensitivity testing is not routinely done. The rationale for treatment with topical antimicrobials is primarily to prevent the exposed stroma from becoming infected and a simple ulcer becoming complicated with the risk of corneal perforation and globe loss. Both gram-positive (beta-hemolytic Streptococcus spp) and gram-negative bacteria can cause ulcer progression; thus, combination antimicrobial drops are used. Common combinations include bacitracin (gram-positive) or gramicidin (gram-positive), neomycin (gram-positive and gram-negative) and polymyxin B (gram-negative).
Before treatment, it is optimal to have a confirmed diagnosis with a combination of cytology, culture, and/or PCR assay. In clinical practice, however, treatment typically starts while awaiting the results of these tests, if indeed any of them are done. Antivirals are often used empirically to help manage clinical signs and slow or stop disease progression. Topical and systemic antiviral drugs are mainly used to treat feline herpesvirus (FHV-1). They have also been used in dogs with viral keratitis (canine herpesvirus Canine Herpesvirus Infection Canine herpesvirus infection is a systemic viral infection that affects puppies worldwide, with mortality rates often reaching 100% in affected litters. Clinical signs, though severe, are nonspecific... read more ) and horses with keratitis and conjunctivitis thought to be associated with equine herpesvirus Equine Herpesvirus Infection Equine herpesviruses are ubiquitous worldwide, with EHV-1 and EHV-4 having the greatest clinical importance in causing respiratory disease in horses. Fever, nasal discharge, malaise, pharyngitis... read more (EHV-2). All antiviral drugs are used off-label. Success in treating ocular herpesvirus in humans does not translate into success against FHV-1, and some drugs (eg, valacyclovir) are toxic to cats.
Topical Antivirals for Ocular Disorders in Animals
Trifluridine (trifluorothymidine) is licensed for use in humans for treatment of herpetic keratitis. The mechanism of action is to inhibit DNA polymerase. Trifluridine has better binding affinity for viral DNA polymerase than for mammalian DNA polymerase. It is an analog of thymidine (pyrimidine) which, when incorporated, causes mis-sense mutations, thus stopping viral replication. As with all antiviral drugs, it is only virostatic. Trifluridine has good penetration through corneal epithelium and reaches therapeutic stromal concentrations. Frequent use can cause conjunctival irritation. Another adverse effect that can affect compliance in administration to cats is that it needs to be administered frequently and it stings on application.
Idoxuridine is only available as a topical formulation from compounding pharmacies. Concentrations are usually 0.1% solution or 0.5% ointment. Because it is very similar to thymidine and is incorporated into cells, frequent topical use can cause corneal toxicity. Corneal penetration is poor when the epithelium is intact.
Cidofovir is an analogue of cytosine (pyrimidine). It is also only available as a compounded drop, usually as a 0.5% solution. Cidofovir has a long half-life due to intracellular accumulation and so can be used less frequently. It is efficacious against feline herpesvirus when administered every 12 hours, which can improve compliance. Chronic use in humans has been associated with nasolacrimal stenosis, and care should be taken with chronic use in cats.
Acyclovir is not very efficacious against feline herpesvirus and is not the topical antiviral of choice. Ganciclovir has a similar mechanism of action to acyclovir; however, it is much more efficacious in vitro than acyclovir and cidofovir. Ganciclovir inhibits viral DNA polymerase and following incorporation into viral DNA blocks replication. It is available as a 0.15% ophthalmic gel or can be compounded as a 0.5% solution with the addition of interferon alpha-2B.
Systemic/Oral Antivirals for Ocular Disorders in Animals
Systemic antiviral drugs to treat feline ocular herpesvirus are needed only in circumstances when topical antiviral treatment is not effective or used in combination.
Acyclovir has also been used at 200 mg, PO, every 8–12 hours. It has poor bioavailability, and repeated dosing can cause systemic toxicity (bone marrow suppression). Therefore it is not recommended as a first-line treatment.
Famciclovir is a purine analog of guanosine and a prodrug of penciclovir. Conversion to the active compound penciclovir involves two steps, with the last step requiring aldehyde oxidase. Cats have very low levels of this enzyme, which has some effect on pharmacokinetics. Oral dosing of famciclovir in cats has been debated. Doses of 40 mg/kg every 8 hours or 90 mg/kg every 12 hours are now recommended, having shown an improved clinical response in naturally infected cats. Adverse effects are mostly gastrointestinal. Famciclovir is metabolized by the liver and excreted by the kidneys. The dosing interval should be extended in cats with kidney disease. There is less cytotoxicity, and the drug has a longer half-life.
Ancillary Treatments for Ocular Disorders in Animals
Lifelong treatment with oral l-lysine (250–500 mg/day) has been recommended to help prevent or reduce the severity of recurrent feline herpesvirus infections. The results are ambiguous as to whether this amino acid supplement reduces viral shedding. In two studies of shelter cats receiving a ration supplemented with oral L-lysine, clinical disease was more severe with increased viral shedding.
Recombinant feline omega interferon and/or human alpha-interferon (5–25,000 IU/day, PO and 10,000–1 million U topically) have also been recommended. They may work by inhibiting replication of herpesvirus and enhancing macrophage activation and lymphocyte-mediated cytotoxicity, but in clinical trials there was no significant treatment effect.
Antifungal drugs are administered by topical and subconjunctival routes for fungal keratitis and by intracameral, intravitreal, and parenteral routes for systemic mycoses. Fungal keratitis is predominantly a problem in horses but can occur in other species (ie, dogs, alpacas, birds). In horses, frequent administration of antifungal drugs in the first 24 hours is thought to cause more corneal inflammation as a result of sudden fungal death and release of intracellular contents. It is recommended empirically that on the first day of treatment, drug be administered every 6 hours, with frequency increased on the second day to every 4 hours.
Topical Antifungals for Ocular Disorders in Animals
Natamycin (pimaricin) is a tetraene polyene antimicrobial. It binds to ergosterol in the cell membrane and causes permeability changes. It is fungicidal when used frequently. After topical application, it enters corneal stroma well but does not reach efficacious concentration in aqueous humor. The recommended treatment is every 2–4 hours initially, for 3 to 4 days, then decreased to every 4–6 hours. Treatment should continue for at least 21–28 days. Small animals can receive drops; equine patients require a subpalpebral lavage for this frequency of application.
Both imidazoles (miconazole) and triazoles (fluconazole, itraconazole, and voriconazole) are used. As a group, they are fungistatic. The mechanism of action is to inhibit the synthesis of ergosterol by binding to the enzyme lanosterol C-14 demethylase. Lack of ergosterol allows the incorporation of other sterols into the cell membrane, resulting in less stability and also affects its barrier function. Potency depends on the affinity of the azole for the enzyme. Triazoles have better affinity than imidazoles also resulting in fewer adverse effects. Topical azoles are all used off-label.
Miconazole has good corneal penetration and has reasonable efficacy against equine Aspergillus and Fusarium isolates. It can be used successfully in dogs and cats with keratomycosis. Miconazole is available as a 2% dermatologic or vaginal cream. The vaginal preparation is less likely to cause ocular irritation. The cream can be difficult to apply because it can make the area around the globe greasy. Ointment formulations are not recommended for use. Miconazole can also be compounded as a 1% solution.
Fluconazole is not commonly used topically because most filamentous fungi (Aspergillus, Fusarium) causing keratomycosis in horses are resistant.
Itraconazole has a somewhat better spectrum against Aspergillus and other filamentous fungi than fluconazole; however, most Fusarium isolates are resistant. Its poor solubility prevents good corneal penetration. A 1% itraconazole/30% DMSO formulation provides high corneal levels of itraconazole ; however, aqueous humor levels are not detectable.
Voriconazole is a newer triazole, similar in structure to fluconazole. Used as a 1% solution, it has better corneal penetration and reaches therapeutic concentrations in aqueous humor. It has a much better spectrum against Aspergillus and Fusarium isolates than other azoles. A 5% solution has been used intrastromally for treatment of stromal abscesses (5%). Intravitreal injection can be administered to dogs with intraocular disease from systemic blastomycosis Blastomycosis in Animals Blastomycosis is a multifocal fungal infection due to the dimorphic fungi Blastomyces spp. The fungi are often found in soil or decomposing organic matter, such as leaves. Infection is... read more .
Silver sulfadiazine (1%) is available in a cream for topical treatment of burns. The silver ions bind to DNA and inhibit synthesis. The ions also bind to surface membranes and proteins causing membrane leakage. Silver sulfadiazine has been associated with eye irritation; however, it may be a treatment of last resort in some cases of equine keratomycosis.
Systemic Antifungals for Ocular Disorders in Animals
Amphotericin B is a polyene antimicrobial that works by binding ergosterol in the fungal plasma membrane. This causes leakage of fungal cell electrolytes resulting in cell death. It is effective against most systemic fungal pathogens (Blastomyces dermatitidis, Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum, Candida spp, and some Aspergillus spp). Efficacy is concentration dependent. Administration can be oral or intravenous. The oral formulations have variable bioavailability, so intravenous administration is preferred. Various formulations are available (phospholipids, cholesteryl sulfate complex, liposomal complexes). Lipid formulations may cause less toxicity. A number of dosing protocols are published for use, usually diluted in 5% dextrose. Dose-dependent renal toxicity is the most common adverse effect. Pretreatment fluid loading with 0.9% sodium chloride is recommended.
Azoles have fewer adverse effects than amphotericin B. Fluconazole and itraconazole are used for treatment of systemic fungal disease (blastomycosis Blastomycosis in Animals Blastomycosis is a multifocal fungal infection due to the dimorphic fungi Blastomyces spp. The fungi are often found in soil or decomposing organic matter, such as leaves. Infection is... read more , coccidiomycosis Coccidioidomycosis in Animals Coccidioidomycosis (valley fever) is a dustborne, noncontagious infection due to Coccidioides spp fungi. These fungi form mycelial mats in shallow arid soil; the mycelium fragments form... read more , cryptococcosis Cryptococcosis in Animals Cryptococcosis is a systemic fungal disease that often affects the respiratory tract (especially the nasal cavity), CNS, eyes, and skin. The causal fungi exist in tissues in an encapsulated... read more and histoplasmosis Histoplasmosis in Animals Histoplasmosis is a chronic, noncontagious, disseminated, granulomatous disease of humans and other animals due to the dimorphic fungus Histoplasma capsulatum var capsulatum. The... read more ) in small animals and in horses as part of a treatment regimen for keratomycosis.
Fluconazole is highly water soluble, has good distribution throughout the body, and is excreted primarily via the kidneys, so dose adjustment is needed in animals with kidney disease. It penetrates well into the aqueous humor and is used to treat blastomycosis in dogs (up to 10–12 mg/kg/day), although itraconazole is more efficacious. For treatment of systemic cryptococcosis, dosages in cats range from 2.5–5 mg/kg every 24 hours, 50 mg/cat/day or 100 mg/cat/day (single or divided dose). In dogs, the dosage is 2.5–10 mg/kg/day. Coccidiomycosis can be treated with 2.5–10 mg/kg/day. Treatment may be required for 6–12 months.
Itraconazole is lipophilic and available as capsules and an oral solution. Oral bioavailability can be variable depending on the formulation. Bioavailability increases when administered with food. In a number of species, compounded itraconazole formulations have been shown to not be bioequivalent and are not recommended. Dosages of 10 mg/kg every 24 hours and 5 mg/kg every 12 hours for 2 months are equally as effective against ocular and systemic blastomycosis. Other regimens are 5 mg/kg every 12 hours for 5 days and then every 24 hours for 90 days. Urine antigen levels can be used to monitor disease resolution. A dosage of 10 mg/kg/day can be used in coccidiomycosis and histoplasmosis.
Voriconazole is well absorbed in horses and, when used at 3 mg/kg every 12 hours for 10 days, reaches therapeutic concentration in the precorneal tear film and aqueous humor. In dogs, voriconazole has been used infrequently for the treatment of systemic fungal infections. After oral dosing, it has a short half-life, and chronic dosing can result in decreased plasma concentration from induction of metabolic enzymes. Oral dosing every 12 hours is likely needed. Adverse effects are usually GI with inappetance and diarrhea. Intravenous use in dogs causes severe toxicity. It should not be used in cats because notable adverse reactions involving the GI tract, eyes and neurologic function (ataxia and hindlimb paresis) have been reported.
Posaconazole is similar in structure to itraconazole and has been used in cats and dogs. Bioavailability increases when taken with food. It is available as a 40 mg/mL suspension or 100 mg slow-release tablets. Dose ranges for animals have not been established based on pharmacokinetic data. In dogs, use of the oral suspension requires dosing (5 mg/kg) every 12 hours. Because of the 42-hour half-life in dogs dosed with the slow-release tablets, every-other-day dosing (5 mg/kg) is recommended. Cats have been treated with 5 mg/kg/day using the oral suspension with doses of 12–15 mg/kg/day also recommended.
For More Information
Also see pet health content regarding drugs used to treat eye disorders Drugs Used to Treat Eye Disorders The 3 primary methods of administering medications to the eye are topical, local ocular (such as under the conjunctival tissue or into the vitreous portion of the eye), and systemic (given by... read more .